Heidelberg symposium

Article

Attend the Heidelberg symposium, Next Generation Retinal Imaging: Multi-Modality Tracking Laser Tomography, at the 8th Euretina meeting in Vienna

Friday 23 May 13:00 - 14:00Next Generation Retinal Imaging: Multi-Modality Tracking Laser TomographyModerator: F. Holz, GERMANY

13.00 F. Holz GERMANYIntroduction

13.05 S. Wolf SWITZERLANDSpectralis Technology: Benefits of real time eye tracking in multi-modality cSLO / SD-OCT imaging

13.20 F. Holz GERMANYSpectralis applications in macular diseases — a new horizon

13.35 G. Coscas FRANCEAngiography combined with SD-OCT imaging for diagnosis and treatment follow-up of vascularised PED

13.50 ALLPanel Discussion

14.00 F. Holz GERMANYClosing remarks

 

Sponsored by

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
Related Content
A brain and a fungus mushroom both depicted in illustration. Concept image for fungal infection and diabetic eye disease. Image credit: ©Anson – stock.adobe.com – generated with AI

Fungal infection and vision impact in patients with diabetic eye disease

Lynda Charters
July 25th 2025
Article

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

Two empty medical syringes on a gradient blue and white surface. Concept image for methotrexate for intravitreal injection for retinitis pigmentosa, European Medicines Agency (EMA) orphan drug designation announcement. Image credit: ©cassis – stock.adobe.com

EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies

Hattie Hayes
July 24th 2025
Article

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

The flags of the European Union (left) and Germany (right), in Berlin, in front of the German parliament. Concept image for European Commission, European Medicines Agency and European myopia atropine drug launch. Image credit: ©respiro888 – stock.adobe.com

Germany serves as European launch point for low-dose atropine from Santen (Ryjunea)

Emily Kaiser Maharjan
July 22nd 2025
Article

The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California

Site Logo

Early Experience of Aflibercept 8mg (EYLE® 8mg) in Routine Clinical Practice

July 22nd 2025
Article
© 2025 MJH Life Sciences

All rights reserved.